Review Article

CME Article: Osteonecrosis in Sickle Cell Disease

Authors: Zan A. Naseer, BS, Malick Bachabi, MD, Lynne C. Jones, PhD, Robert S. Sterling, MD, Harpal S. Khanuja, MD

Abstract

Osteonecrosis is one of the most devastating musculoskeletal manifestations of sickle cell disease and most commonly affects the femoral head. Although the exact pathophysiology of this condition in patients with sickle cell disease is unknown, it is suggested that red cell sickling and repetitive vaso-occlusion may be associated with tissue hypoxia, inflammation, and subsequent bone necrosis and collapse. If left untreated, osteonecrosis can be extremely debilitating and may lead to severe pain, loss of function, and degenerative joint changes. Although several conservative management approaches exist, total joint arthroplasty remains the most effective treatment intervention. A multidisciplinary approach among the primary care physician, hematologist, and orthopedic surgeon is essential in optimizing patient management.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Centers for Disease Control and Prevention. Sickle cell disease (SCD): data & statistics. http://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed June 28, 2016.
 
2. Al-Mousawi FR, Malki AA. Managing femoral head osteonecrosis in patients with sickle cell disease. Surgeon 2007;5:282-289.
 
3. Perfetti DC, Boylan MR, Naziri Q, et al. Does sickle cell disease increase risk of adverse outcomes following total hip and knee arthroplasty? A nationwide database study. J Arthroplasty 2015;30:547-551.
 
4. Poignard A, Flouzat-Lachaniette CH, Amzallag J, et al. The natural progression of symptomatic humeral head osteonecrosis in adults with sickle cell disease. J Bone Joint Surg Am 2012;94:156-162.
 
5. Diggs LW, Bell A. Intraerythrocytic hemoglobin crystals in sickle cell-hemoglobin C disease. Blood 1965;25:218-223.
 
6. Vaishya R, Agarwal AK, Edomwonyi EO, et al. Musculoskeletal manifestations of sickle cell disease: a review. Cureus 2015;7:e358.
 
7. Ulug P, Vasavda N, Awogbade M, et al. Association of sickle avascular necrosis with bone morphogenic protein 6. Ann Hematol 2009;88:803-805.
 
8. Baldwin C, Nolan VG, Wyszynski DF, et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood 2005;106:372-375.
 
9. Pandey S, Ranjan R, Pandey S, et al. Effect of ANXA2 gene single nucleotide polymorphism (SNP) on the development of osteonecrosis in Indian sickle cell patient: a PCR-RFLP approach. Indian J Exp Biol 2012;50:455-458.
 
10. Hedhli N, Falcone DJ, Huang B, et al. The annexin A2/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol 2012;2012:406273.
 
11. Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005;37:435-440.
 
12. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005;19:771-784.
 
13. Cabannes R, Mambo-Sambo F. Anatomical and pathological aspects of bone changes in sickle cell disease. In: Arlet J, Ficat RP, Hungerford DS , eds. Bone Circulation. Philadelphia: Williams & Wilkins, 1984.
 
14. Sherman M. Pathogenesis of disintegration of the hip in sickle cell anemia. South Med J 1959;52:632-637.
 
15. Malizos KN, Siafakas MS, Fotiadis DI, et al. An MRI-based semiautomated volumetric quantification of hip osteonecrosis. Skeletal Radiol 2001;30:686-693.
 
16. Collaborative Osteonecrosis Group. Symptomatic multifocal osteonecrosis. A multicenter study. Clin Orthop Relat Res 1999;369:312-326.
 
17. Flouzat-Lachaniete CH, Roussignol X, Poignard A, et al. Multifocal joint osteonecrosis in sickle cell disease. Open Orthop J 2009;3:32-5.
 
18. American College of Radiology. ACR Appropriateness Criteria® avascular necrosis (osteonecrosis) of the hip. National Guideline Clearinghouse. http://guideline.gov/content.aspx?id=15734&ampsearch=avascular+necrosis. Accessed September 18, 2014.
 
19. Arlet J, Ficat P, Lartigue G. Mode of onset of primary osteonecrosis of the femoral head. (Stage I. Uncomplicated). Study of 20 cases histologically verified by punch biopsy. Rev Rhum Mal Osteoartic 1968;35:239-249.
 
20. Sugano N, Atsumi T, Ohzono K, et al. The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head. J Orthop Sci 2002;7:601-605.
 
21. Mont MA, Marulanda GA, Jones LC, et al. Systematic analysis of classification systems for osteonecrosis of the femoral head. J Bone Joint Surg Am 2006;88(Suppl 3):16-26.
 
22. Jawad MU, Haleem AA, Scully SP. In brief: Ficat classification: avascular necrosis of the femoral head. Clin Orthop Relat Res 2012;470:2636-2639.
 
23. Gardeniers JWM. The ARCO Staging System: Generation and Evolution Since 1991. In: Koo KH, Mont MA, eds. Osteonecrosis. New York: Springer, 2014.
 
24. Aguilar C, Vichinsky E, Neumayr L. Bone and joint disease in sickle cell disease. Hematol Oncol Clin North Am 2005;19:929-941.
 
25. Mont MA, Zywiel MG, Marker DR, et al. The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review. J Bone Joint Surg Am 2010;92:2165-2170.
 
26. Hernigou P, Bachir D, Galacteros F. The natural history of symptomatic osteonecrosis in adults with sickle-cell disease. J Bone Joint Surg Am 2003;85-A:500-504.
 
27. Hernigou P, Daltro G. Osteonecrosis in sickle-cell disease. In: Koo KH, Mont MA, eds. Osteonecrosis. New York: Springer, 2014.
 
28. Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Res 1993;289:136-143.
 
29. Kennon JC, Smith JP, Crosby LA. Core decompression and arthroplasty outcomes for atraumatic osteonecrosis of the humeral head. J Shoulder Elbow Surg 2016;pii:S1058-2746. 00060-4.
 
30. Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 2006;88:1117-1132.
 
31. McGrory BJ, York SC, Iorio R, et al. Current practices of AAHKS members in the treatment of adult osteonecrosis of the femoral head. J Bone Joint Surg Am 2007;89:1194-1204.
 
32. Koren L, Ginesin E, Melamed Y, et al. Hyperbaric oxygen for stage I and II femoral head osteonecrosis. Orthopedics 2015;38:e200-e205.
 
33. Neumayr LD, Aguilar C, Earles AN, et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am 2006;88:2573-2582.
 
34. Kamath AF, McGraw MH, Israelite CL. Surgical management of osteonecrosis of the femoral head in patients with sickle cell disease. World J Orthop 2015;6:776-782.
 
35. Mukisi-Mukaza M, Manicom O, Alexis C, et al. Treatment of sickle cell disease’ hip necrosis by core decompression: a prospective case-control study. Orthop Traumatol Surg Res 2009;95:498-504.
 
36. Bozic KJ, Zurakowski D, Thornhill TS. Survivorship analysis of hips treated with core decompression for nontraumatic osteonecrosis of the femoral head. J Bone Joint Surg Am 1999;81:200-209.
 
37. Styles LA, Vichinsky EP. Core decompression in avascular necrosis of the hip in sickle-cell disease. Am J Hematol 1996;52:103-107.
 
38. Al Omran A. Multiple drilling compared with standard core decompression for avascular necrosis of the femoral head in sickle cell disease patients. Arch Orthop Trauma Surg 2013;133:609-613.
 
39. Steinberg ME, Larcom PG, Strafford B, et al. Core decompression with bone grafting for osteonecrosis of the femoral head. Clin Orthop Relat Res 2001;386:71-78.
 
40. Chang T, Tang K, Tao X, et al. Treatment of early avascular necrosis of femoral head by core decompression combined with autologous bone marrow mesenchymal stem cells transplantation. Zhongguo Xiufu Chongjian Waike Zazhi 2010;24:739-743. Article in Chinese.
 
41. Korompilias AV, Lykissas MG, Beris AE, et al. Vascularised fibular graft in the management of femoral head osteonecrosis: twenty years later. J Bone Joint Surg Br 2009;91:287-293.
 
42. Hsu JE, Wihbey T, Shah RP, et al. Prophylactic decompression and bone grafting for small asymptomatic osteonecrotic lesions of the femoral head. Hip Int 2011;21:672-677.
 
43. Soucacos PN, Beris AE, Malizos K, et al. Treatment of avascular necrosis of the femoral head with vascularized fibular transplant. Clin Orthop Relat Res 2001;386:120-130.
 
44. Al-Mousawi F, Malki A, Al-Aradi A, et al. Total hip replacement in sickle cell disease. Int Orthop 2002;26:157-161.
 
45. Hernigou P, Zilber S, Filippini P, et al. Total THA in adult osteonecrosis related to sickle cell disease. Clin Orthop Relat Res 2008;466:300-308.
 
46. Issa K, Naziri Q, Maheshwari AV, et al. Excellent results and minimal complications of total hip arthroplasty in sickle cell hemoglobinopathy at mid-term follow-up using cementless prosthetic components. J Arthroplasty 2013;28:1693-1698.
 
47. Jack CM, Howard J, Aziz ES, et al. Cementless total hip replacements in sickle cell disease. Hip Int 2016;26:186-192.
 
48. Gulati Y, Sharma M, Bharti B, et al. Short term results of cementless total hip arthroplasty in sicklers. Indian J Orthop 2015;49:447-451.
 
49. Hanker GJ, Amstutz HC. Osteonecrosis of the hip in the sickle-cell diseases. Treatment and complications. J Bone Joint Surg Am 1988;70:499-506.
 
50. Jeong GK, Ruchelsman DE, Jazrawi LM, et al. Total hip arthroplasty in sickle cell hemoglobinopathies. J Am Acad Orthop Surg 2005;13:208-217.
 
51. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011;365:2453-2462.
 
52. Ponnusamy KE, Kim TJ, Khanuja HS. Perioperative blood transfusions in orthopaedic surgery. J Bone Joint Surg Am 2014;96:1836-1844.
 
53. Sathappan SS, Ginat D, Di Cesare PE. Multidisciplinary management of orthopedic patients with sickle cell disease. Orthopedics 2006;29:1094-1103.
 
54. Lebouvier A, Poignard A, Coquelin-Salsac L, et al. Autologous bone marrow stromal cells are promising candidates for cell therapy approaches to treat bone degeneration in sickle cell disease. Stem Cell Res 2015;15:584-594.